PATENT CLAIM ANALYSIS

Application Number: 15767371
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "337000"]

Abstract:
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof are antagonists of leukotriene B 4  receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B 4  receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension. Non-alcoholic fatty liver disease/nonalcoholic steatoepatitis metabolic syndrome, atherosclerosis, and cancer.

Claim (Index 20):
The compound according to  claim 1  selected from:\n (1) 4-Fluoro-2-((3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)-N-((trifluoro-methyl)sulfonyl)benzamide; \n (2) 4-Fluoro-2-((3R,4S)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)-N-((trifluoro-methyl)sulfonyl)benzamide; \n (3) 4-Fluoro-2-((3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)-N-(methyl-sulfonyl)benzamide; \n (4) 4-Fluoro-2-((3R,4S)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)-N-(methyl-sulfonyl)benzamide; \n (5) N-(Cyclopropylsulfonyl)-2-((3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)benzamide; \n (6) N-(Cyclopropylsulfonyl)-2-((3R,4S)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)benzamide; \n (7) 2-((3S,4R)-4-Hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)-N-((1-methylcyclo-propyl)sulfonyl)benzamide; \n (8) 2-((3R,4S)-4-Hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)-N-((1-methylcyclo-propyl)sulfonyl)benzamide; \n (9) 4-Fluoro-2-((3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)-N-((1-methyl-cyclopropyl)sulfonyl)benzamide; \n (10) 4-Fluoro-2-((3R,4S)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)-N-((1-methyl-cyclopropyl)sulfonyl)benzamide; \n (11) N-(tert-Butylsulfonyl)-2-((3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)benzamide; \n (12) N-(tert-Butylsulfonyl)-2-((3R,4S)-4-hydroxy-3-(pyridin-2-)ylmethyl)chroman-7-yl)benzamide; \n (13) N-(tert-Butylsulfonyl)-4-fluoro-2-((3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)benzamide; \n (14) N-(tert-Butylsulfonyl)-4-fluoro-2-((3R,4S)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)benzamide; \n (15) N-(Cyclopropylsulfonyl)-4-fluoro-2-((3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)benzamide; \n (16) N-(Cyclopropylsulfonyl)-4-fluoro-2-((3R,4S)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)benzamide; \n (17) 2-((3,4-trans)-4-Hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)-N-(isobutylsulfonyl)-benzamide; \n (18) N-((Cyclopropylmethyl)sulfonyl)-2-((3,4-trans)-4-hydroxy-3-(pyridin-2-ylmethyl)-chroman-7-yl)benzamide; \n (19) N-(Cyclopentylsulfonyl)-2-((3,4-trans)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)benzamide; \n (20) 2-((3,4-trans)-4-Hydroxy-3-(pyridin-2-)ylmethyl)chroman-7-yl)-N-(neopentylsulfonyl)-benzamide; \n (21) 2-((3S,4R)-3-Benzyl-4-hydroxychroman-7-yl)-N-((1-methylcyclopropyl)sulfonyl)-benzamide; \n (22) 2-((3R,4S)-3-Benzyl-4-hydroxychroman-7-yl)-N-((1-methylcyclopropyl)sulfonyl)-benzamide; \n (23) 2-((3S,4R)-3-Benzyl-4-hydroxychroman-7-yl)-N-(cyclopropylsulfonyl)benzamide; \n (24) 2-((3R,4S)-3-Benzyl-4-hydroxychroman-7-yl)-N-(cyclopropylsulfonyl)benzamide; \n (25) 2-(Rac-trans)-4-Hydroxy-3-(thiazol-4-ylmethyl)chroman-7-yl)-N-((1-methyl-cyclopropyl)sulfonyl)benzamide; \n (26) 2-((3S, 4R)-4-Hydroxy-3-(thiazol-4-ylmethyl)chroman-7-yl)-N-((1-methylcyclopropyl)-sulfonyl)benzamide; \n (27) 2-((3R,4S)-4-Hydroxy-3-(thiazol-4-ylmethyl)chroman-7-yl)-N-((1-methylcyclopropyl)-sulfonyl)benzamide; \n (28) 2-(Rac-trans)-4-Hydroxy-3-((1-methyl-1H-pyrazol-5-yl)methyl)chroman-7-yl)-N-((1-methylcyclopropyl)sulfonyl)benzamide; \n (29) 2-((Rac-trans)-4-Hydroxy-3-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)chroman-7-yl)-N-((1-methylcyclopropyl)sulfonyl)benzamide; \n (30) 2-((Rac-trans)-3-((1-ethyl-1H-pyrazol-5-yl)methyl)-4-hydroxychroman-7-yl)-N-((1-methylcyclopropyl)sulfonyl)benzamide; \n (31) N-(tert-Butylsulfonyl)-2-((rac-trans)-4-hydroxy-3-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)chroman-7-yl)benzamide; \n (32) N-(tert-Butylsulfonyl)-2-((rac-trans)-4-hydroxy-3-(thiazol-4-ylmethyl)chroman-7-yl)benzamide; \n (33) N-(tert-Butylsulfonyl)-2-((3S,4R)-4-hydroxy-3-(thiazol-4-ylmethyl)chroman-7-yl)benzamide; \n (34) N-(tert-Butylsulfonyl)-2-((3R,4S)-4-hydroxy-3-(thiazol-4-ylmethyl)chroman 7-yl)benzamide; \n (35) N-(tert-Butylsulfonyl)-2-((rac-trans)-4-hydroxy-3-((1-methyl-1H-pyrazol-5-yl)methyl)chroman-7-yl)benzamide; \n (36) N-(tert-Butylsulfonyl)-2-((rac-trans)-3-((1-ethyl-1H-pyrazol-5-yl)methyl)-4-hydroxychroman-7-yl)benzamide; \n (37) N-(tert-Butylsulfonyl)-2-((3S,4R)-3-((1-ethyl-1H-pyrazol-5-yl)methyl)-4-hydroxychroman-7-yl)benzamide; \n (38) N-(tert-Butylsulfonyl)-2-((3R,4S)-3-((1-ethyl-1H-pyrazol-5-yl)methyl)-4-hydroxychroman-7-yl)benzamide; \n (39) 2-((Rac-cis)-3-([1,1\u2032-Biphenyl]-4-ylmethyl)-4-hydroxychroman-7-yl)-4-fluoro-N-((trifluoromethyl)sulfonyl)benzamide; \n (40) 2-((Rac-trans)-3-([1,1\u2032-Biphenyl]-4-ylmethyl)-4-hydroxychroman-7-yl)-4-fluoro-N-((trifluoromethyl)sulfonyl)benzamide; \n (41) 2-((3R,4S)-3-([1,1\u2032-Biphenyl]-4-ylmethyl)-4-hydroxychroman-7-yl)-4-fluoro-N-((trifluoromethyl)sulfonyl)benzamide; \n (42) 2-((3S,4R)-3-([1,1\u2032-Biphenyl]-4-ylmethyl)-4-hydroxychroman-7-yl)-4-fluoro-N-((trifluoromethyl)sulfonyl)benzamide; \n (43) 2-(Rac-trans)-4-hydroxy-3-((2-phenyloxazol-4-yl)methyl)chroman-7-yl)-N-((1-methylcyclopropyl)sulfonyl)benzamide; \n (44) 2-((3R,4S or 3S,4R)-4-Hydroxy-3-((2-phenyloxazol-4-yl)methyl)chroman-7-yl)-N-((1-methylcyclopropyl)sulfonyl)benzamide; \n (45) 2-((3S,4R or 3R,4S)-4-hydroxy-3-((2-phenyloxazol-4-yl)methyl)chroman-7-yl)-N-((1-methylcyclopropyl)sulfonyl)benzamide; \n (46) 2-(Rac-trans)-4-Hydroxy-3-((2-phenyloxazol-4-yl)methyl)chroman-7-yl)-N-((1-methylcyclopropyl)sulfonyl)benzamide \n (47) N-(tert-Butylsulfonyl)-2-((3R,4S)-4-hydroxy-3-((2-phenyloxazol-4-yl)methyl)chroman-7-yl)benzamide; \n (48) N-(tert-Butylsulfonyl)-2-((3S,4R)-4-hydroxy-3-((2-phenyloxazol-4-yl)methyl)chroman-7-yl)benzamide; \n (49) 2-((3,4-trans)-4-Hydroxy-3-((R)-1-(pyridin-2-yl)ethyl)chroman-7-yl)-N-((1-methylcyclopropyl)sulfonyl)benzamide; and \n (50) 2-((3,4-trans)-4-Hydroxy-3-((S)-1-(pyridin-2-yl)ethyl)chroman-7-yl)-N-((1-methylcyclopropyl)sulfonyl)benzamide; \n or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.67241
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15768097', '15769079', '13614534', '13140997', '16334391']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8090297724720118
- 35 USC 102 Novelty (BERT): 0.6111326155852279
- Combined Prediction Score: 0.7892400567833334
- Mean Citation Score: 413.685834
- Max Citation Score: 580.38086
- Similarity Product: 481.2831677754904

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test